Beschreibung
Fluconazole inhibits CYP3A4 and CYP2C19, increasing aripiprazole plasma concentrations and the risk of aripiprazole adverse effects.
Mechanismus
Aripiprazole is metabolized by CYP3A4 and CYP2D6; fluconazole inhibition of CYP3A4 reduces aripiprazole clearance, potentially increasing exposure by 30–50%.
Klinische Bedeutung
Elevated aripiprazole levels may cause akathisia, sedation, and metabolic adverse effects; dose adjustment may be needed.
Maßnahmen
Reduce aripiprazole dose by approximately 50% during fluconazole co-therapy; monitor for adverse effects and restore dose after antifungal completion.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.